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Post-Traumatic Stress Disorder: Evidence-Based Research for the
Third Millennium
Javier Iribarren3, Paolo Prolo1,2, Negoita Neagos2 and Francesco Chiappelli1,2
1UCLA School of Dentistry, 2Psychoneuroimmunology Group, Inc. and 3David Geffen School of
Medicine at UCLA, Los Angeles, CA, USA
The stress that results from traumatic events precipitates a spectrum of psycho-emotional and
physiopathological outcomes. Post-traumatic stress disorder (PTSD) is a psychiatric disorder that results
from the experience or witnessing of traumatic or life-threatening events. PTSD has profound psycho-
biological correlates, which can impair the person’s daily life and be life threatening. In light of current
events (e.g. extended combat, terrorism, exposure to certain environmental toxins), a sharp rise in
patients with PTSD diagnosis is expected in the next decade. PTSD is a serious public health concern,
which compels the search for novel paradigms and theoretical models to deepen the understanding of
the condition and to develop new and improved modes of treatment intervention. We review the current
knowledge of PTSD and introduce the role of allostasis as a new perspective in fundamental PTSD
research. We discuss the domain of evidence-based research in medicine, particularly in the context
of complementary medical intervention for patients with PTSD. We present arguments in support of
the notion that the future of clinical and translational research in PTSD lies in the systematic evaluation
of the research evidence in treatment intervention in order to insure the most effective and efficacious
treatment for the benefit of the patient.
Keywords: post-traumatic stress syndrome – allostasis – evidence-based research – complementary
medicine
Introduction
Post-Traumatic Stress Disorders
The twenty-first century rose in a ray of hope. The belief was
commonly held that an age of worldwide prosperity was begin-
ning with the new millennium. Only a few years ago, people
spoke of peace. Today, the general trend in many populations
across the globe is fear and anxiety about self and neighbor.
Socio-political events have cast a shadow of uneasiness about
one’s own security and that of significant others at a personal
as well as a societal level. (Case in point is Greg, a business-
man from Southern California, who happened to be on a busi-
ness trip in New York city scheduled for September 10–12,
2001. Following the 9/11 attack, which he barely escaped, he
immediately attempted to contact his family in the Southland
and to leave New York city. He was on the first plane out:
but the plane never took off, instead it was boarded by the
New York city SWAT team who, at gun point, arrested a pas-
senger seated four seats in front of Greg’s. Greg then drove at
night to Philadelphia, where he was eventually able to board a
plane and return to his anxious family. To this day, Greg does
not fly as often as before, is reticent to fly to the east coast and
will not return to do business in New York city. His Type II
diabetes has considerably worsened.)
Traumatic events are profoundly stressful. The stress that
results from traumatic events precipitates a spectrum of
psycho-emotional and physiopathological outcomes. In its gra-
vest form, this response is diagnosed as a psychiatric disorder
consequential to the experience of traumatic events.
Post-traumatic stress disorder, or PTSD, is the psychiatric
disorder that can result from the experience or witnessing of
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traumatic or life-threatening events such as terrorist attack,
violent crime and abuse, military combat, natural disasters,
serious accidents or violent personal assaults. Exposure to
environmental toxins (e.g. Agent orange, electromagnetic radi-
ation) may result in immune symptoms akin to PTSD in many
susceptible patients (1,2).
Subjects with PTSD often relive the experience through
nightmares and flashbacks. They report difficulty in sleeping.
Their behavior becomes increasingly detached or estranged
and is frequently aggravated by related disorders such as
depression, substance abuse and problems of memory and cog-
nition. The disorder soon leads to impairment of the ability to
function in social or family life, which more often than not res-
ults in occupational instability, marital problems and divorces,
family discord and difficulties in parenting. The disorder can
be severe enough and last long enough to impair the person’s
daily life and, in the extreme, lead the patient to suicidal tend-
encies. PTSD is marked by clear biological changes, in addi-
tion to the psychological symptoms noted above, and is
consequently complicated by a variety of other problems of
physical and mental health.
PTSD—A Brief History
Whereas the terminology of PTSD arose relatively soon fol-
lowing the Vietnam conflict, the observation that traumatic
events can lead to this plethora of psychobiological manifesta-
tions is not new. During the Civil War, a PTSD-like disorder
was referred to as the ‘Da Costa’s Syndrome’ (3), from the
American internist Jacob Mendez Da Costa (1833–1900; Civil
War duty: military hospital in Philadelphia).
The syndrome was first described by ABR Myers (1838–
1921) in 1870 as combining effort fatigue, dyspnea, a sighing
respiration, palpitation, sweating, tremor, an aching sensation
in the left pericardium, utter fatigue, an exaggeration of symp-
toms upon efforts and occasionally complete syncope. It was
noted that the syndrome resembled more closely an abandon-
ment to emotion and fear, rather than the ‘effort’ that normal
subjects engage to overcome challenges (4). This classic
observation pertains to what we now know of allostasis, as
we discuss below. Da Costa reported in 1871 that the dis-
order is most commonly seen in soldiers during time of stress,
especially when fear was involved (3). The syndrome became
increasingly observed during the Civil War and during
World War I.
PTSD in the US Population Today
The National Center for PTSD (US Department of Veterans
Affairs) made public estimates that whereas the lifetime pre-
valence of PTSD in the US population was 5% in men and
10% in women in the mid-to-late 1990s, the prevalence of
PTSD among Vietnam veterans at this same time was at
15.2%. About 30% of the men and women who have spent
time in more recent war zones experience PTSD.
Whereas the onset and progression of PTSD is characteristic
for every individual subject, data suggest that most people who
are exposed to a traumatic, stressful event will exhibit early
symptoms of PTSD in the days and weeks following exposure.
Available data from the National Center for PTSD suggest that
8% of men and 20% of women go on to develop PTSD and
30% of these individuals develop a chronic form that persists
throughout their lifetimes. Complex PTSD, which is also
referred to as ‘disorder of extreme stress’, results from expos-
ure to prolonged traumatic circumstances, such as the year-on
end threat of insurgent attacks among our military personnel
currently in active deployment.
The National Center for PTSD also estimates that under nor-
mal and usual socio-political conditions 8% of the US popula-
tion will experience PTSD at some point in their lives, with
women (10.4%) twice as likely as men (5%) to develop
PTSD. At the beginning of the millennium, it was estimated
that 5–6 million US adults suffered from PTSD. Because of
the traumatic developments of recent years, and of ongoing
turmoil worldwide, it is possible and even probable that the
incidence of PTSD will sharply increase within the next dec-
ade and that it may become one among the most significant
public health concerns of this new century. This threat is all
the more serious considering the fact that PTSD symptoms
seldom disappear completely; recovery from PTSD is a
lengthy, ongoing, gradual and costly process, which is often
hampered by continuing reaction to memories. Treatment
usually aims at reducing reactions and to diminishing the
acuity of the reactions. Treatments also seek to increase the
subject’s ability to manage trauma-related emotions and to
greater confidence in coping abilities.
Focus of this Review
This work discusses our current understanding about PTSD. It
explores current developments in stress research and discusses
its applications and implication to the complex psychobiolo-
gical prognosis of PTSD. The work concludes by presenting
a view into the future of PTSD treatment from the perspective
of evidence-based medicine, which many regard as the break-
open research of the next decades—systematic and critical
research on research to establish and determine what is the
best available evidence for treatment for the patients. Indeed,
this will be particularly true in the case of subjects with
PTSD, if the austere predictions of a sharp rise in prevalence
consequential to most recent terrorist and war events world-
wide that involve US soldiers and civilians prove true.
Current Views on PTSD
Assessment
There are different psychiatric rating instruments and scales
that can be used to assess adult PTSD. Some are part of com-
prehensive diagnostic manuals or instruments: DSM-IV TR
(diagnostic criteria for 309.81 PTSD) (5); ICD-10 (F43.1
PTSD, from the International Statistical Classification of
Diseases and Related Health Problems, 10th revision); the
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PTSD module, within the Structured Clinical Interview for
DSM-IV (6) or the PTSD Keane scale (PK scale) (7), within
the Minnesota Multiphasic Personality Inventory-2 (MMPI-2).
Some are designed as either self-reports or as clinician-
administered instruments specifically assessing adult PTSD:
Davidson Trauma Scale (8); Distressing Event Questionnaire
(9); Impact of Event Scale-Revised (10); Trauma Symptom
Checklist-40 (11); PTSD Checklist-Civilian Version (12);
Revised Civilian Mississippi Scale for PTSD (13); the
Posttraumatic Stress Diagnostic Scale (14); Trauma Symptom
Inventory (11); Los Angeles Symptom Checklist (15) or the
Clinician-Administered PTSD Scale (CAPS) (16).
The underlying phenomena of PTSD are probably centrally
mediated. Case in point is a study targeting women with early
childhood abuse-related PTSD that found correlates of the
emotional Stroop (17). Subjects with and without PTSD were
compared. Both groups underwent PET scanning while per-
forming in the color and emotional Stroop tasks and control
condition. The control condition involved naming the color
of rows of XXs (red, blue, green and yellow). The active color
condition involved naming the color of color words (again
with the same four colors), while the semantic context of the
word was incongruous with the color. The active emotional
condition involved naming the color (again the same four col-
ors) of emotionally charged words (rape, bruise, weapon, and
stench). These words have been shown to produce emotional
arousal (18). The study examined the effectiveness of the
Stroop task as a probe of anterior cingulate function in
PTSD, because of the role of the anterior cingulate and medial
prefrontal cortex in stress response and emotional regulation.
After comparing it with the color Stroop, the emotional Stroop
displayed significantly decreased blood flow among the PTSD
subjects in the anterior cingulate. Performance in the color
Stroop task produced a non-specific activation of the anterior
cingulate in both the PTSD and non-PTSD abused women.
However, the emotional Stroop produced a relatively lower
level blood flow response of anterior cingulate among PTSD
abused women. These observations may indicate that PTSD
anterior cingulate dysfunction is specific to the neural circuitry
of the processing of emotional stimuli. Shin et al. (19) con-
firmed a relative decrease in blood flow in anterior cingulate
activation in combat-related PTSD and also displayed a
decreased blood flow for the emotional (but not color)
Stroop. Taken together, these findings indicate that PTSD
may have a neural component, which could significantly alter
psychoneuroendocrine-immune regulation, as discussed
below.
PTSD Assessment in the Military
Certain scales have been developed that specifically target
military personnel.
(i) PTSD Checklist-Military Version (12).
(ii) The Mississippi Scale for Combat-Related PTSD
(M-PTSD), specifically a screening and diagnostic
instrument for combat-related PTSD (20), which
validated as well for treatment seeking (21) and com-
munity samples (22).
(iii) The Combat Exposure Scale measures the level of war
time stress of veterans, an instrument with strong
internal consistency (a ¼ 0.85) as well as a high
test–retest reliability (r ¼ 0.97) (23).
(iv) The PK scale, a subscale of the MMPI-2, whose items
were selected based on their ability to differentiate
among veterans diagnosed with PTSD and those who
were not. This scale has strong reliability (a ¼ 0.95)
and good test–retest reliability (r ¼ 0.94) (7).
(v) The SCID PTSD module is frequently used to assess
presence of PTSD among veterans as well (24,25).
(vi) Additional scales have been used to target assessment
of PTSD among veterans, including the M-PTSD
(26–29), the PK scale (30,31) or the CAPS (29,32).
The prevalence of PTSD diagnosis varies depending on the
assessment method. One study compared three measures of
PTSD among American and Korean War prisoners of war
(POWs). It compared an unstructured self-report interview
measure, the M-PTSD and the DSM-III-R SCID instrument.
The data showed that partially unstructured interviews and
the M-PTSD yielded PTSD prevalence rates of 31 and 33%,
respectively, which were significantly higher than the rate of
26% yielded by the SCID. Both the unstructured clinical inter-
view and the M-PTSD had equal accuracy, consistently disag-
reeing with the SCID from 7 to 15% of assessed cases (33).
Such differences in rates, depending on the assessment
instrument may hold significance. According to the study
(33) there may be different explanations; self-report instru-
ments like the M-PTSD do not reflect DSM criteria as compre-
hensibly as the SCID. Symptoms may differ in both intensity
and kind among older and younger prisoners of war. In the
paradoxical side, it is possible for an individual to be dia-
gnosed with PTSD while reporting minimal stress levels; in
fact, subjective stress can be seen as a confounding factor
that can have an influence on diagnosis (34).
A PTSD-negative clinical interview occurring simultan-
eously with a PTSD confirmation of PTSD (or also with a
moderate-to-lowM-PTSD score) may be indicative of chronic,
but stable, PTSD. Such chronic and stable PTSD may not be
clinically relevant and may not require focused intervention.
They recommend to measure symptom intensity with such
instruments as the CAPS (16). Such an approach could
decrease PTSD-positive diagnoses among subjects with low
levels of distress (33).
Allostasis and PTSD
Allostasis and the Response to Stress
Allostasis refers to the psychobiological regulatory process
that brings about stability through change of state consequen-
tial to stress. Psycho-emotional stress can be defined as a per-
ceived lack, or loss of fit of one’s perceived abilities and the
demands of one’s inner world or the surrounding environment
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(i.e. person/environment fit). Traumatic events that trigger
PTSD are perfect examples of such onerous demands that
lead to the conscious or unconscious perception on the part
of the subject of not being able to cope (35).
The perception of stress is often associated with psycholo-
gical manifestations of anxiety, irritability and anger, sad and
depressed moods, tension and fatigue, and with certain bodily
manifestations, including perspiration, blushing or blanching
of the face, increased heart beat or decreased blood pressure,
and intestinal cramps and discomfort. These signs mirror the
spectrum of psychobiological symptoms in PTSD. These
manifestations are generally associated with the nature of the
stress, its duration, chronicity and severity. A group of symp-
toms, now referred to as the sickness behavior, is also noted
that is associated with clinically relevant changes in the bal-
ance between the psychoneuroendocrine and the immune
systems (35–37).
It was the renowned nineteenth-century French physiologist,
Claude Bernard (1813–1878) who first proposed that defense
of the internal milieu (le milieu inte´rieur, 1856) is a funda-
mental feature of physiological regulation in mammalian sys-
tems, whence the phrase ‘homeostasis’ was coined. By the
early 1930s, Walter Cannon (1871–1945) proposed that organ-
isms engage in a dynamic process of adjustment of the physio-
logical balance of the internal milieu in response to changing
environmental conditions. Hans Selye (1907–1982) estab-
lished the cardinal points of the ‘Generalized Stress Response’
in his demonstration of concerted physiological responses to
stressful challenges.
Stress alters the regulation of both the sympathetic and the
parasympathetic branches of the autonomic nervous system,
with consequential alterations in hypothalamic control of the
endocrine response controlled by the pituitary gland. Auto-
nomic activation and the elevation of hormones, including
those produced by the hypothalamic-pituitary-adrenal axis,
play a pivotal role in regulating cell-mediated immune surveil-
lance mechanisms, including the production of cytokines that
control inflammatory and healing events (35,36). In brief, the
perception of stress leads to a significant load upon physiolo-
gical regulation, including circadian regulation, sleep and
psychoneuroendocrine-immune interaction.
In brief, stress is profound alterations in the cross-regulation
and interaction of the hormonal-immune regulatory axis. The
experience of stress, as well as that of traumatic events and
the anxiety-laden recollections thereof, produce a primary
endocrine response, which involves the release of glucocortic-
oids (GCs). GCs regulate cellular immune activity in vivo sys-
temically and locally. They block the production of pro-
inflammatory cytokines (e.g. interleukin[IL]-1b IL-6) and
TH1 cytokines (e.g. IL-2) at the molecular level in vitro and
in vivo, but may have little effects upon TH2 cytokines (e.g.
IL-4). The net effect of challenging immune cells with GC is
to impair immune T cell activation and proliferation, while
maintaining antibody production. The secretion of GC by the
adrenal cortex is under the control of the anterior pituitary
adrenocorticotropin hormone (ACTH). Immune challenges
release pro-inflammatory cytokines (e.g. IL-1b, IL-6), which
induce hypothalamic secretion of the ACTH inducing factor
corticotropin releasing factor (CRF) in animal and in human
subjects. Stressful stimuli also lead to the significant activation
of the sympathetic nervous system and a rise in the levels of
pro-inflammatory cytokines (i.e. IL-1b and IL-6). It follows
that the consequences of stress are not uniform. The psycho-
pathological and the physiopathological impacts of stress
may be significantly greater in certain people, compared with
those of others. The impact of stress is dynamic and multifa-
ceted and the same person may exhibit a variety of manifesta-
tions of the psychoneuroendocrine-immune stress response
with varying degrees of severity at different times. The out-
come of stress can be multivalent (35).
Allostasis and Heterostasis
The term ‘heterostasis’ arose from stress research to describe
the situation where the demands upon the organism exceed
its inherent physiological limiting capacity. Sterling and Eyer
(38) used the term ‘allostasis’ to describe the events that
involve mind–body systemic regulation to recover from stress,
rather than local feedback. Allostatic regulation now signifies
the recovery and the maintenance of internal balance and viab-
ility amidst changing circumstances consequential to stress.
It encompasses a range of behavioral and physiological func-
tions that direct the adaptive function of regulating homeo-
static systems in response to challenges (37–39).
The cumulative load of the allostatic process is the allostatic
load. The pathological side effects of failed adaptation are the
allostatic overload. Allostasis pertains to the psychobiological
regulatory system with variable set points. These set points are
characterized by individual differences. They are associated
with anticipatory behavioral and physiological responses and
are vulnerable to physiological overload and breakdown of
regulatory capacities (39,40).
Type 1 allostatic load utilizes, as it were, stress responses as
a means of self-preservation by developing and establishing
temporary or permanent adaptation skills. The organism aims
at surviving the perturbation in the best condition possible
and at normalizing the normal life cycle. In Type 2 allostatic
load, the stressful challenge is excessive, sustained or contin-
ued and drives allostasis chronically. An escape response can-
not be found. Type I versus type II allostatic responses
curiously reiterate Myers’ observations that his patients seem
to abandon themselves to the emotion and the fear that assailed
them, rather than engage in the effort to counter and to over-
come the challenge, which normal subjects typically under-
took. Future research in PTSD from the perspective of
allostasis may reveal a learned helplessness component, which
could become key in the development and evaluation of treat-
ment interventions (Fig. 1).
Allostasis and PTSD
It is clear that stress research and PTSD research are inter-
twined. Psychobiological manifestations in PTSD and in
506 Post-traumatic stress disorder
complex PTSD (disorder of extreme stress) evidently pertain
to the same domain of mind–body interactions, which are
elucidated in psychoneuroimmunology research.
The stress response, more than likely, underlies the psycho-
biological sequelae of PTSD. The relevance of the field of cur-
rent research on allostasis to PTSD is all the more evident
when one considers that subjects position themselves along a
spectrum of allostatic regulation, somewhere between
allostasis (i.e. toward regaining physiological balance) and
the allostatic overload (i.e. toward physiological collapse and
associated potential onset of varied pathologies).
In brief, the recent advances in our understanding of the
adaptation of the organism to stressful challenges, the allo-
static process, present a new and a rich paradigm for research
in the psychobiology of PTSD. Future research must investig-
ate whether or not the dichotomy of Type I and Type II allo-
static responses will provide an effective theoretical model
for the development of novel and improved modes of interven-
tion to treat PTSD.
PTSD—Paving the Future
Treatment
The treatment of PTSD is complex, both in terms of available
treatments and the myriad of trauma possibilities that cause it.
Properly diagnosing PTSD according to DSM-IV criteria
should be the first step, including assessing for co-morbidity.
This should be followed by treatments with various degrees
of demonstrated efficacy (41).
Historically, it was in the early eighties when research on the
treatment efficacy for PTSD began, with multitude of case
studies dealing with different kinds of PTSD having been
produced since then. Overall, both cognitive behavioral
approaches and selective serotonin reuptake inhibitor regimes
have been proved to be effective to deal with different kinds
of PTSD. At the same time, there is also evidence that other
treatment modalities, such as psychodynamic psychotherapy,
hypnotherapy, eye movement desensitization and reprocessing
can be effective as well; albeit their evidence is derived from
less numerous and less well-controlled studies (i.e. open trials
or case reports) (41,42). In terms of combined treatments,
historically there has not been a systematic effort to address
the value of combining medication with psychotherapy and/
or combinations of medications. PTSD intervention is com-
plicated further by the fact that co-morbidities (e.g. substance
abuse, over-the-counter medication abuse, psychiatric dis-
orders including major depression) are common. Particularly
in situations where co-morbidity exists, a combined appro-
ached should be considered.
In addition, there are other considerations affecting the treat-
ment appropriateness:
(i) type of PTSD inducing trauma;
(ii) PTSD chronicity and
(iii) gender, number of times being exposed to trauma
and age.
Of interest due to the perilous state of the world (i.e. wars and
terrorism) is the issue of the type of PTSD inducing trauma.
Combat causes high rates of PTSD and makes it more ref-
ractory to treatment than other PTSD-inducing traumas (43).
According to experts, combat veterans with PTSD may be
less responsive to treatment that other victims of other
traumatic exposures (41,42). It is still unclear why combat-
related PTSD is more resistant to treatment than PTSD caused
by other traumas. Following is a list of possible reasons:
(i) a great degree of psychopathology presented by
patients seeking help at Veterans Administration
hospitals;
(ii) isolation from support and help upon returning home
and
(iii) potential for secondary gain, such as disability benefits
(42).
Combat-caused PTSD is often associated with other psychiat-
ric disorders, including depression, anxiety, mood disorders
and substance abuse disorders (22). More specifically, 57–
62% of Croatian Balkan war veterans diagnosed with PTSD
also met co-morbid diagnoses criteria (44), with the most com-
mon being depression (Muck-Seller et al., 2003), alcohol, drug
abuse, phobias, panic disorders and psychosomatic and psy-
chotic disorders (45). In terms of PTSD-associated psychotic
symptomatology, between 30 and 40% of combat-related
PTSD subjects may go on to develop psychotic symptomato-
logy (45,46).
Allostatic load:
adaptation
ALLOSTASIS
maintaining stability through change
Type I Allostatic Response Type II Allostatic Response
Allostatic overload:
no adaptation
Stress
Figure 1. Allostasis refers to the psychobiological regulatory process that
brings about stability through change of state consequential to stress. Allostatic
regulation describes the recovery and the maintenance of internal balance and
viability amidst changing circumstances consequential to stress. It encom-
passes the Type 1 allostatic load that reflects the utilization by the organism
of the range of behavioral and physiological functions that direct the adaptive
function of regulating homeostatic systems in response to challenges (i.e. stress
response) to develop temporary or permanent adaptation skills by means of
self-preservation. Type 1 allostatic responses translate the organism aims at
surviving the perturbation in the best condition possible and at normalizing
the normal life cycle. By contrast, the Type 2 allostatic responses reflect a
load to the organism that is excessive, sustained, or continued, and drives
allostasis chronically and that precludes effective escape from the stress. The
Type 1 and Type 2 allostatic response dichotomy provides a theoretical model
for future research and treatment of PTSD and complex PTSD.
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It is usually believed that the most effective treatment
results are obtained when both PTSD and the other disorder(s)
are treated together rather than one after the other. It is
becoming increasingly critical to ascertain this position
because the prevalence of PTSD and disorder of complex
stress is bound to rise sharply in the next decade consequential
to the present multinational state of alert and anxiety follow-
ing ongoing tragic, wanton and widespread terrorism and
particularly with respect to combat-related PTSD in present
times.
Psychotherapeutic Interventions
Psychotherapeutic approaches have a long tradition in PTSD
treatment, including combat-induced PTSD. Some have
more proven efficacy than others. Some of these approaches
may be appropriate to address the initial stages of trauma.
Psychological debriefing is an intervention given shortly after
the occurrence of a traumatic event. The goal is to prevent the
subsequent development of negative psychological effects.
In fact, psychological debriefing approaches to PTSD can be
described as semi-structured interventions aimed at reducing
initial psychological stress. Strategies include emotional
processing via catharsis, normalization and preparation for
future contingencies (47). Gulf War veterans who underwent
psychological debriefing showed no significant differences
in their scores of two scales measuring PTSD when compared
with the control group (48). In general, there is little evid-
ence of psychological debriefing approaches effectively
acting to prevent psychopathology, although participants
seem to be open to it, which may indicate its usefulness as a
rapport builder or as a screening tool. In general however,
there is a lack of rigorously conducted research in this
area. To this day there is paucity in the data to orient the
treatment of combat-related PTSD for veterans (49). The
International Consensus Group on Depression and Anxiety
supports that exposure psychotherapy is the most appropriate
approach for this disorder (41), although this approach does
not show a significant influence on PTSD’s negative sympto-
matology, such as avoidance, impaired relationships or anger
control (49).
In terms of proven efficacy, cognitive behavior therapy and
eye movement desensitization and reprocessing are effective
approaches to deal with PTSD (50–54), while other psycho-
therapeutic approaches (e.g. humanistic or psychodynamic
interventions) do not have enough evidence to draw strong
conclusions on their utility (42). Cognitive-behavioral psycho-
therapy encompasses a myriad of approaches (i.e. systematic
desensitization, relaxation training, biofeedback, cognitive
processing therapy, stress inoculation training, assertiveness
training, exposure therapy, combined stress inoculation train-
ing and exposure therapy, combined exposure therapy and
relaxation training and cognitive therapy). There are empirical
studies focusing on PTSD treatment dealing with combat-
related PTSD. Vietnam veterans receiving exposure therapy
displayed improvement as evidenced in terms of reducing
intrusive combat memories (55), physiological responding,
anxiety (56), depression and feelings of alienation, while
also promoting increased vigor and skills confidence (57).
Exposure therapy, combined with a standard treatment also
showed effectiveness with other Vietnam veterans in terms
of subject self-report symptoms related to the traumatic
experiences, sleep and subjective anxiety responding to trauma
stimuli (58).
Pharmacotherapy
Pharmacotherapy is another approach utilized to deal with
PTSD, including combat-induced PTSD. In fact, typically,
there is a combination of psychotherapy and medication treat-
ments to treat chronic PTSD (59). In general, the different
co-morbidities associated with PTSD play a role in the kinds
of pharmacotherapeutic treatments used for its treatment.
Antidepressants and other medications commonly used are
tricyclic antidepressants, monoamine oxidase inhibitors, selec-
tive serotonin reuptake inhibitors, antianxiety and adrenergic
agents and mood stabilizers (60). Sertraline has been found
effective to reduce PTSD symptomatology (61,62). In 1999,
the United States Food and Drug Administration (FDA)
approved sertraline as an appropriate treatment for PTSD.
In fact it is the only drug to receive FDA approval to specific-
ally combat PTSD. Sertraline and fluoxetine have produced
clinical improvements among PTSD patients in randomized
clinical trials (63). Paroxetine, another selective serotonin
reuptake inhibitor like sertraline, is also habitually used to treat
chronic PTSD (59). Mirtazapine was another successful agent
when used in the treatment of PTSD afflicted Korean veterans
(64). In addition, Olanzapine and fluphenazine have been suc-
cessfully used with combat-induced PTSD subjects from the
Balkans. Both medicines were successful in ameliorating
both PTSD and psychotic symptomatology (43).
Rigorous, well-controlled methods are necessary for
conducting studies on the efficacy of PTSD treatments.
Well-controlled studies are characterized by the following
characteristics:
(i) clearly defined symptoms, as well as inclusion/
exclusion criteria;
(ii) measures used are reliable and valid, with solid
psychometric properties;
(iii) utilization of blind evaluators in order to minimize
expectancy and demand biases;
(iv) properly trained evaluators to ensure reliability and
validity;
(v) the chosen intervention programs are specific, replic-
able and manualized in order to maximize consistent
intervention delivery;
(vi) there is no biased assignment to treatment, which helps
maximize that any detected differences and/or similar-
ities are attributable to the treatment technique and not
to other causes and
(vii) use of treatment adherence ratings in order to ascertain
if intervention parameters were followed (41).
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Research on Research in PTSD: Role of Evidence-Based
Research and Complementary Alernative Medicine
Future clinical research in PTSD requires the stringent, rigor-
ous and systematic approach provided by evidence-based
medicine. Evidence-based research in medicine goes beyond
the routine narrative literature review. It systematically evalu-
ates the strength of the available evidence and generates a con-
sensus statement of the best available evidence in the form of a
systematic review of the available research (Fig. 2).
The future of clinical and translational research in PTSD lies
in the systematic evaluation of the research evidence in treat-
ment intervention for the patients. This type of ‘research on
research’ endeavor requires attentive library search of the pub-
lished materials (e.g. clinical trials) and informal individual
communications with the individual researchers and authors.
The collected evidence is then evaluated for research quality
along certain standards [e.g. the consolidated standards of ran-
domized trials (CONSORT)] and by means of validated instru-
ments (e.g. Timmer scale, Jadad scale and Wong scale) (65).
The data from separate reports are pooled, when appropriate,
for meta-analysis, meta-regression and individual patient
data analyses. The data are analyzed from the perspective of
Bayesian modeling in order to interpret data from research
in the context of external evidence and judgments (65).
In the context of the treatment of patients with PTSD and
co-morbidities, it is important and timely to generate a system-
atic review of the clinical research evidence for joint and sim-
ultaneous treatment of PTSD and the co-morbidities versus a
staggered approach. The summative evaluation of the outcome
of such a systematic review will generate a consensus state-
ment that will establish whether or not the problem was framed
in a clinically relevant manner (e.g. were the patient popula-
tion, predictor variables and outcome measures clearly iden-
tified and relevant to the treatment of PTSD and its
co-morbidities within the confines of the research?). The state-
ment must discuss the validity of the process of integration
(e.g. were the prospective inclusion and exclusion criteria
clearly identified? Was the search comprehensive and expli-
citly described? Was the validity of the individual studies
adequately assessed? Were the process of study selection,
searching, assessing validity and data abstraction reliable?).
The statement also produces evidence about the rigor of the
process by which information was integrated (e.g. were the
individual studies sufficiently similar to warrant their com-
bination in an over-arching hypothesis-driven analysis? Are
the summary findings representative of the largest and most
rigorously performed studies?). The quality, presentation and
relevance of the findings must be discussed (e.g. Are the key
elements of each study clearly displayed? Is the magnitude of
the findings statistically significant? Are the findings homo-
geneous or heterogeneous? Are sensitivity analyses presented
and discussed? Do the findings suggest an overall net benefit
for patients with PTSD?). This concerted, systematic and
scientific-process driven mode of evaluating current treatment
interventions for subjects with PTSD is timely and urgent to
insure that the medical establishment will be prepared to
handle the fast-approaching wave of PTSD cases in the next
decade.
This method-driven approach for the evaluation of clinical
data has merit that its product, the consensus statement, must
also generate a cost-effectiveness analysis (i.e. a process of
decision analysis that incorporates cost) e.g. by a step approach
similar as the above method to assess the following:
(i) whether the problem was framed in a clinically relev-
ant manner,
(ii) the validity of integrated information,
(iii) the rigor of process of integration and
(iv) the presentation and quality of the findings.
The relevant findings in this cost-effectiveness analysis are
usually expressed as the incremental cost-effectiveness bet-
ween joint and simultaneous treatment of PTSD and its
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The scientific Process of Evidence-Based Research:
Implications for Complementary Medicine
Figure 2. Evidence-based research in medicine follows the 5-step scientific
process that includes stating the research question, which in evidence-based
research consists of the PIC/PO question (What is the population being
examined, e.g. patients with PTSD? What are the interventions being looked
at, e.g. conventional treatment versus complementary medicine? Are the inter-
ventions being compared or are predictions being drawn, i.e. meta-analysis
versus meta-regression approach? What is the outcome of interest, e.g. activit-
ies of daily living?). The second step involves methodology, including the
sampling of the research literature, and the tools for the critical analysis of
the reports. The third step refers to design which usually fall under the acronym
CONSORT (i.e. consolidated standards of clinical trials). The fourth step is
concerned with the analysis of the data gathered in the evidence-based research
process. This commonly entails meta-analytical and meta-regression tech-
niques, as well as individual patient data analysis (e.g. number needed to treat,
NNT). Depending upon the tools utilized to evaluate the scientific literature,
scores about the completeness and quality of research methodology, design
and statistical handling of the findings are generated (SESTA, systematic
evaluation of the statistical analysis). These values are analyzed by acceptable
sampling statistical protocols to establish whether or not the sample of research
reports studied by means of the evidence-based process was statistically
acceptable to produce reliable inferences. The last step is a cumulative syn-
thesis, which summarizes the process and the findings. The consensus state-
ment reflects the best available evidence with respect to the stated PIC/PO
question. The process is applied to the performance of systematic reviews,
which are all-encompassing of the available literature. Best case studies in
evidence-based research entail a random performance of the process of
evidence-based research with a random sample of the available literature.
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co-morbidities versus a staggered approach. The incremental
cost-effectiveness ratio, i.e. the difference in costs between
the two strategies divided by the difference in effectiveness
between the two strategies, is often presented as well.
The consensus statement evaluates each competitive strat-
egy, usually by means of the Markov model-based decision
tree. This approach permits to model events that may occur
in the future as a direct effect of treatment or as a side effect.
The model produces a decision tree that cycles over fixed
intervals in time and incorporates probabilities of occurrence.
Even if the difference between the two treatment strategies
appears quantitatively small, the Markov model outcome
reflects the optimal clinical decision, because it is based on
the best possible values for probabilities and utilities incorpor-
ated in the tree. The outcome produced by the Markov decision
analysis is generally obtained by means of the sensitivity ana-
lysis to test the stability over a range of probability estimates
and thus reflects the most rational treatment choice (Fig. 3).
The process of evidence-based research in medicine has
begun its integration in the domain of PTSD. Rose et al. (66)
have established by means of a systematic review of the liter-
ature that the early optimism about brief early psychological
interventions, including debriefing, is actually unfounded and
not supported by the research evidence. These findings con-
firmed earlier Cochrane-based systematic reviews (67,68). In
a separate line of study, systematic reviews established clear
support of the research evidence for serotonin reuptake inhib-
itors as the preferred first line treatment for PTSD, whereas
mood stabilizers, atypical neuroleptics, adrenergic agents and
newer antidepressants were shown to show promise, but to
require further controlled trials to establish their efficacy and
efficaciousness (60,69).
The future of clinical and translational research in PTSD
also lies in its judicious integration of complementary and
alternative medicine (CAM). For instance, whereas PTSD
symptoms are common in patients with breast cancer, this
symptomatology is more effectively reduced by traditional
psychosocial interventions compared with CAM-oriented
intervention (70). Research will determine whether this obser-
vation is true across all forms of PTSD-inducing stress and
trauma and across all subjects.
In conclusion, it is timely to design similar evidence-based
research studies to establish the strength of the evidence in
support of complementary approaches for the treatment of
PTSD. For example, use of complementary therapies (e.g.
massage and herbal/food supplements) is widespread among
active military veterans and their spouses for stress and co-
morbid pain and anxiety. Data indicate that up to 70% of the
surveyed subjects want these interventions available at the
medical treatment facility (e.g. Veterans Administration Med-
ical Center, VAMC), despite sound supportive research data
(71). This trend appears to be particularly evident among
native American veterans, who usually choose not to seek
treatment at VAMC facilities, in part because of the preference
they hold for alternative and complementary treatments, which
are usually not available at those facilities (72). This popula-
tion of patients is therefore at serious risk of remaining under-
served. Among the civilian population, the need for systematic
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Figure 3. The purpose of evidence-based research in medicine is to elucidate the best available evidence in response to a stated clinical problem (e.g. is comple-
mentary medicine effective with patients with PTSD?). Following the scientific process of evidence-based research and the generation of the consensus statement
(Fig. 2), the information is implemented and evaluated by the clinician. Effectiveness and utilities data are estimated (e.g. Markov model) to aid the final clinical
decision-making process (74).
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reviews on the benefit of complementary medicine in the treat-
ment of PTSD is also becoming evident in light of the increas-
ing reports proposing the benefits of massage and acupuncture
in individuals exposed to the traumatic events of 9/11 (73).
Taken together, these developments should produce import-
ant novel information about the fundamental nature of PTSD
from the perspective of allostasis and about its optimal treat-
ment using the best available evidence obtained from system-
atic reviews. This concerted approach will be particularly
important as the prevalence of PTSD with its complex psycho-
biological co-morbidity rises and as alternative and comple-
mentary medical treatments for PTSD emerge and take hold.
Such is, in our view, the future of research in PTSD, in order
to establish a registry of regular critical evaluation updates of
the available evidence for the immediate service of the clinical
research community and the benefit of patients with PTSD,
their families and society at large.
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